• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Marinus Pharmaceuticals, Inc. - Common Stock (NQ:MRNS)

0.5500 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.5500
Bid (Size) 0.5495 (70)
Ask (Size) 0.5500 (172)
Prev. Close 0.5500
Today's Range 0.5500 - 0.5500
52wk Range 0.2202 - 1.970
Shares Outstanding 55,185,622
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 30, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates OMIC, MRNS, VCSA on Behalf of Shareholders
January 07, 2025
From Halper Sadeh LLC
Via GlobeNewswire

Performance

YTD
+3.0%
+3.0%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
+0.6%
+0.6%
1 Year
-57.7%
-57.7%

More News

Read More
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS
January 06, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MoneyLion Inc. (NYSE - ML), Marinus Pharmaceuticals, Inc. (Nasdaq - MRNS), Better Choice Inc. (NYSE American - BTTR), NeueHealth, Inc. (NYSE - NEUE)
January 03, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders
December 31, 2024
From Halper Sadeh LLC
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 30, 2024
Via Benzinga
Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%
December 30, 2024
Via Benzinga
Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
December 30, 2024
From Ademi LLP
Via Business Wire
MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders
December 30, 2024
From Halper Sadeh LLC
Via Business Wire
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
December 30, 2024
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
November 12, 2024
From Marinus Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 29, 2024
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 28, 2024
Via Benzinga
Crude Oil Down 1%; Dow Posts Upbeat Earnings
October 24, 2024
Via Benzinga
Topics Stocks
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
October 24, 2024
Via Benzinga
Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results
October 24, 2024
Via Benzinga
Dow Falls 150 Points; Tesla Posts Upbeat Earnings
October 24, 2024
Via Benzinga
Topics Stocks
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
October 24, 2024
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
October 17, 2024
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
October 15, 2024
From Marinus Pharmaceuticals
Via Business Wire
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
October 11, 2024
Via MarketBeat
Topics ETFs
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
October 09, 2024
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 08, 2024
From Marinus Pharmaceuticals
Via Business Wire
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
October 01, 2024
Via MarketBeat
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
September 20, 2024
From Marinus Pharmaceuticals
Via Business Wire

Frequently Asked Questions

Is Marinus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Marinus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Marinus Pharmaceuticals, Inc. - Common Stock trade on?
Marinus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Marinus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Marinus Pharmaceuticals, Inc. - Common Stock is MRNS on the Nasdaq Stock Market
What is the current price of Marinus Pharmaceuticals, Inc. - Common Stock?
The current price of Marinus Pharmaceuticals, Inc. - Common Stock is 0.5500
When was Marinus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Marinus Pharmaceuticals, Inc. - Common Stock was at 02/10/25 04:00 PM ET
What is the market capitalization of Marinus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Marinus Pharmaceuticals, Inc. - Common Stock is 30.35M
How many shares of Marinus Pharmaceuticals, Inc. - Common Stock are outstanding?
Marinus Pharmaceuticals, Inc. - Common Stock has 30M shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap